I N PATIENTS WITH NONTHYROIDAL ILLNESS, changes
in plasma concentrations of thyroid hormones are frequently found. These alterations in thyroid hormone plasma concentrations in otherwise euthyroid patients are referred to as the euthyroid sick syndrome, t-4 Although the pathogenesis of this euthyroid sick syndrome has not been completely elucidated, several lines of evidence indicate that inflammatory mediators like interleukin-6 (IL6) may be involved. 5 The relationship between IL6 and the euthyroid sick syndrome has been addressed in a number of studies. The serum IL6 concentration was correlated inversely with the triiodothyroniue (T3) level, as well as the T3 to thyroxine (T4) ratio. In patients with acute illness, a positive correlation between IL6 and reverse T3 (rT3) was found, whereas no correlations between tumor necrosis factor alpha (TNF-c0 or ILl and thyroid hormone levels were found. 6-9 In accordance with this, administration of IL6 to patients with renal carcinoma induced a euthyroid sick syndrome within several hours.~° However, IL6 also induced a flu-like syndrome with a number of other biological effects. Therefore, it was uncertain whether the effects of IL6 on thyroid hormone metabolism were a direct consequence of IL6. In this respect, the recent study by Boelen et al t~ is of interest, wherein they describe the effects of acute inflammation induced by endotoxin, turpentine oil, or ListeHa infection in IL6 knockout mice. These mice showed a smaller decrease in T3 levels during the 48 hours after the three inflammatory challenges. These data suggest that IL6 is involved in the pathogenesis of the acute euthyroid sick syndrome.
Although administration of IL6 induced an acute euthyroid sick syndrome within hours in humans, long-term IL6 administration for several weeks was associated with a disappearance of the alterations in thyroid hormone concentrations in the same humans. 1° Therefore, it still remains uncertain whether chronically increased IL6 production is also involved in the alterations of thyroid hormone metabolism in chronic diseases.
Multiple myeloma is a malignant proliferation of plasma ceils in the bone marrow. With respect to IL6 production, multiple myeloma is an interesting disease. IL6 plays a key role in the pathogenesis of the disease] 2 19 and we recently found that IL-6 production rates were two to 30 times higher in these patients than in healthy controls. Moreover, anti-IL6 chimeric monoclonal antibodies (cMabs) strongly suppressed endogenous IL6 production in these patients, probably by blocking a positive feedback loop between IL6 and myeloma cell-induced IL6 production by bone marrow stromal cells. 2° Therefore, the patients from that trial are of interest with respect to the relation between chronic IL6 overproduction and thyroid hormone concentrations. To evaluate the effects of increased IL6 production on thyroid hormone metabolism, we measured thyroid hormone concentrations before, during, and after inhibition of IL6 production and IL6-dependent effects by anti-IL6 cMabs in these patients with multiple myeloma.
SUBJECTS AND METHODS
We studied I2 weight-stable patients (median age, 61.5 years; median body mass index, 25 kg/m 2) during 14 days of treatment with the cMab. Clinical characteristics are shown in Table l. All patients had multiple myeloma according to the criteria of Durie and Salmon, 21 and were either relapsing after or resistant to second-line chemotherapy (vincrisfine, adriamycin, and dexametbasone [VAD] or VAD-like regimens, high doses of melphalan with or without autologous bone malTow or peripheral stem cell support). Exclusion criteria were as follows: age less than 18 or greater than 75 years, life expectancy less than 3 months, Karnofsky score less than 60, diabetes mellitus, hypercalcemia requiring treatment, recent aliogeneic bone marrow transplantation, kidney and/or liver functional abnormalities, coexisting malignancies, and active infection. None of the patient s had a history of thyroid or other endocrine diseases. The patients did not receive any treatment for multiple myeloma at least 1 month before the start of the study. The subjects did not take any medication known to interfere with thyroid hormone metabolism. The study protocol was approved by the institutional medical ethics committee.
Anti-IL6 cMab
To circumvent possible induction of human antimouse antibodies, a murine-human anti-IL6 cMab (chimeric CLB IL6/8) was developed. It was constructed of the antigen-binding variable region of the murine anti-IL6 antibody (CLB IL6/8) and the constant region of a human IgG1-K immunoglobulin. This cMab has a high affinity for recombinant and native IL6 (Kd = 6.25 × 10 -12 tool/L). 2°,22 The cMab (chimeric CLB IL6/8) was developed at Centocor (Malvern, PA) and manufactured by Centocor Europe (Leiden, The Netherlands).
Treatment Schedule
Anti-lL6 cMabs were administered daily by 2-hour infusions for 14 days. Before treatment, a test dose of the cMab (10 gg intravenously) was given over 5 minutes. Since none of the patients developed an immediate hypersensitivity reaction, treatment was started 15 minutes later. The first three patients received the cMab 5 mg/d intravenously, the next three patients received 10 mg/d, patients no. 7 to 9 received 20 mg/d, and the last three patients received 40 mg/d. Eight O f 12 patients received a complete second treatment of 14 days' duration with a similar dosage as in the first treatment cycle of anti-IL6 cMab, starting 14 days after the end of the first treatment cycle.
Plasma samples for IL6, cMab, and C-reactive protein (CRP) were taken five times per week and stored at -80°C until the patient completed the study. Routine samples for thyroid hormone concentrations were taken on days 0, 7, 14, 28, and 41 and analyzed immediately. The samples were drawn before starting infusion of anti-IL6.
Assays
IL6 levels were determined by the B9 bioassay as described previously. 2°,a3 One unit of B9-stimulating acti;eity was defined as the amount inducing half-maximal proliferation, and it corresponded to 1 pg IL6. To determine the total IL6 level (ie, free 1L6 plus IL6 complexed to Mab), an excess (10 ~g/mL) of a second anti-IL6 Mab (CLB IL6/14) was added to each well to displace IL6 from binding with the in vivo administered, neutralizing chimeric CLB IL6/8. CLB IL6/14 and CLB IL6/8 Mabs recognize partly overlapping sites of IL6. Htowever, CLB IL6/14 is not capable of inhibiting IL6 activity in the B9 bioassay, z4
During treatment with the cMab, actual free IL6 levels cannot be measured, because dilution of the samples necessary for testing in the B9 bioassay or enzyme-linked immunosorbent assay (ELISA) immediatelY influences the equilibrium between the IL6-cMab complex, free IL6, and free cMab. TherefQre, free IL6 levels were calculated Using the Henderson-Hasselbach equation, with the Kd, serum cMab levels, and total IL6 levels as known parameters.
Levels of the CLB IL6/8 cMab were determined using a radioimmunoassay (RIA) as described previously. 2° The threshold of this assay is 13.5 ng/mL Mab. ILl was determined using the D10bioassay 25 (normal value, undetectable)and TNF by ELISA (Central Laboratory Bloodtransfusion, Amsterdam, The Netherlands; normal value, <50 pg/mL).
Thyroid hormones were determined by the following assays: thyrotropin (TSI-I) by TSH-ICMA (Behring, Marburg, Germany; normal value, 0.4 to 4.0 mU/L; intraassay variation, 6.8%; interassay variation, 5.7%); T3 by in-house RIA (normal value, 1.3 to 2.9 nmol/L; intraassay variation, 4.0%; interassay variation, 6.3%); rT3 by in-house RIA (normal value, 0.11 to 0.44 nmol/L; intraassay variation, 4.6%; interassay variation, 4.6%); T 4 by in-house RI A (normal values, 70 to 150 nmol/L; intJ:aassay variation, 3.0%; interassay variation, 5.1%); free T4 (fr4) by SPAC fT4-fraction (Byk-Sangte c Diagnostica, Dietzenbach, Germany; normal value, 10.0 to 20.0 pmol/L; intraassay variation, 2.8%; interassay variation, 5.7%); T3 uptake by a commercial kit (T3-uptake (MAA) kit; Kodak Clinical Diagnostics, Amersham, England; normal value, 0.84 to 1. i 1; intraassay variation, 2.7%; interassay . variation, 2.3%); thyroid peroxidase (TPO) autoantibodies (anti-TPO) by a commercial luminescence immunoassay (LIA; Lumitest anti-TPO; Brahms, Berlin, Germany); and antithyroglobulin antibodies by a homemade assay using 125I-TG and IgG antibodies. C-reactive protein (CRP) was determined by nephelometry (Behring; normal value, <5 mg/L).
Statistical Analysis
The effect of treatment with anti-IL6 cMab was evaluated by ANOVA for randomized block design and Fisher's least-significant difference test, when appropriate, or the Wilcoxon rank test. Significance was set at P less than .05.
RESULTS
Twelve patients (three per dosage group) completed at least one treatment cycle of 14 days, and eight of them also completed a secon d treatment cycle. Patient no. 1 received only 2 days of the second treatment cycle, because he needed radiotherapy for myeloma-related neurological complications. His thyroid hormone concentrations were determined and remained within normal limits until day 100. Patient no. 5 (dosage group 10 rag/d) and patient no. 9 (20 mg/d), only completed the first treatment cycle because of infectious complications, and patient no. 12 (40 rag/d) received anti-IL6 from days 1 to 4 and 16 to 29 because she had a fever Of Unknown origin on day 5.
Pretreatment Thyroid Hormone Concentrations
Pretreatment thyroid hormone levels showe d multiple abnormalities (Table 2 ). Both plasma T4 and T3 concentrations were decreased in patients no. 3 and 7. In patient no. 3, this was associated with a decreased fT4 concentration. Nonetheless, in EFFECTS OF ANTI-IL6 Mabs ON THYROID HORMONES both subjects, plasma TSH concentrations were not increased.
In patients no. 6 and 8, plasma fT 4 concentrations were decreased despite normal total T4 concentrations. This was associated with a decreased T 3 concentration and a decreased T3]'F4 ratio in patient no. 8 (13.1 × 10-3; normal range, 14.9 to 21.9 × 10-3). In both patients no. 6 and 8, plasma TSH levels were increased. In patients no. 1 and 5, only plasma T3 concentrations were decreased compared with the normal range. In patient no. 11, fT4 concentration was slightly increased, with normal T4 and TSH levels. Plasma rT3 concentration was increased only in patient no. 12. Only two of 12 patients had thyroid hormone concentrations that were all within the normal reference range of our laboratory. Anti-TPO and anti-TG autoantibodies were not detectable in any of the patients.
The median pretreatment IL6 level was 11.5 pg/mL in these patients, and only one (no. 2) had a normal IL6 level (Table 2) . There was no significant correlation between pretreatment serum IL6 and thyroid hormone concentrations in these patients (rT3/IL6, r = -.06; T3/IL6, r = -.22; TSH/IL6, r = .08; and T4/IL6, r = -.08).
Effects of Infusion of Anti-IL6 cMabs
There were no toxicities or allergic reactions related to the cMab. During treatment with the cMab, IL6 circulates as a biologically ineffective complex with the cMab. The median serum half-life of the cMab was 17.8 days, resulting in an accumulation and high serum levels of the cMab. Mean peak serum levels of the cMab were between 6.7 ~tg/mL in patient no. 1 (5 rng/d antML6 cMab) and 288 gg/mL in patient no. 11 (40 mg]d). 26 The CRP level, which is IL6-dependenty was below detection level during treatment with the cMab. 2° In accordance, free IL6 levels decreased rapidly to less than 0.3 pg/mL in all patients (Fig 1) . No difference in the efficacy of blocking IL6 activity between the different dosage groups was found, and already in the lowest dosage group, the high-affinity cMab was 
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circulating in excess. Thus, no dose-response relation between the different dosage groups was found.
Despite these profound changes in IL6 levels, there were no significant changes in thyroid hormone concentrations during cMab treatment (Fig 2) . This was also true for the five patients with low pretreatment T 3 levels when analyzed as a separate group (data not shown). Eight of 12 patients received a second complete treatment cycle. Their thyroid hormone levels before the second treatment cycle were not different from the pretreatment values for the first treatment with the anti-IL6 cMab. There were no significant effects of anti-IL6 treatment on thyroid hormone concentrations in these eight patients during the second treatment with antML6 cMab (Fig 2) .
Thyroid Hormone Levels in Patients With Infections During Anti-IL6 Treatment
Patient no. 5, who completed the first treatment cycle, had fever due to a urinary tract infection with Escherichia coli and negative blood culture results at the time she was admitted on day 28 for the second treatment cycle (Fig 3A) . Therefore, a second treatment cycle of anti-IL6 cMab was not given, and she was treated with antibiotics. Free IL6 levels increased to a maximal 32 pg/mL at day 37, at which time T 3 concentrations were decreased and rT3 concentrations were increased. Plasma TSH and T 4 levels remained within normal limits. In this patient, TNF-o~ and ILl levels remained below the detection limit in all samples. The CRP level increased from less than 3 mg/L (day 21) to a maximum of 130 mg/L at day 37.
In patient no. 9, anti-IL6 cMab was stopped during the second treatment cycle at day 34, because she developed a high fever and low blood pressure due to pneumonia and septicemia caused by Staphylococcus aureus (Fig 3B) . At day 34 (the day before she died), plasma cMab was 16.3 pg/mL, and total serum IL6 was elevated to 356,000 pg/mL, of which only a minor part (36 pg/mL) was not bound to the cMab. In this patient, plasma T 3 decreased, associated with an increase in plasma rT3. Plasma T4, fT4, and TSH remained within normal limits. CRP increased from less than 3 mg/L (day 33) to 245 mg/L at day 34. TNF-c~ and ILl levels were not determined.
DISCUSSION
In this study, we investigated whether IL6 affects thyroid hormone metabolism in multiple myeloma, a chronic IL6-mediated disease. There was no effect on thyroid hormone concentrations when serum IL6 was neutralized and endogenous IL6 production was totally inhibited by the anti-lL6 cMab. Before anti-IL6 treatment, 10 of 12 patients had abnormal thyroid hormone concentrations, and all but one had increased IL6 concentrations. However, there was no correlation between these thyroid hormone and IL6 concentrations. From these observations, we conclude that chronically elevated IL6 concentrations do not seem to play a major role in thyroid hormone metabolism in multiple myeloma.
We studied patients with multiple myeloma who were resistant to second-line chemotherapy. This group appears to have multiple abnormalities in thyroid hormone concentrations. Five of 12 patients had decreased T3 concentrations consistent with a euthyroid sick syndrome. However, none of these five had increased rT 3 concentrations. Although patient no. 12 had an increased rT3 level before anti-IL6 treatment, we cannot exclude the possibility of a specific effect of multiple myeloma on rT3 levels. For instance, the euthyroid sick syndrome in renal disease is also characterized by the absence of an increase in rT3 concentrations. 8 However, we are not aware of data on thyroid hormone concentrations in patients with multiple myeloma. Two patients (no. 6 and 8) had slightly increased plasma TSH values associated with decreased fI'4 concentrations. Although it is possible that there was mild hypothyroidism in these patients, plasma TSH values can also be increased in the euthyroid sick syndrome. 4 In line with the euthyroid sick syndrome, the T3/T 4 ratio was decreased in patient no. 8. Moreover, in both patients, no thyroid autoantibodies were detectable. Because treatment with anti-IL6 cMabs did not affect thyroid indices in these two patients with increased TSH levels, and exclusion of these two patients from the analyses did not affect our results (data not shown), our conclusions as to the lack of a correlation between IL6 and thyroid hormone concentrations are not affected by inclusion of these patients.
Anti-IL6 cMabs were administered well in excess of circulating IL6 concentrations, even in patients who received the lowest dose (cMab 5 mg/d). Almost all free IL6 was complexed by the surplus of antibodies (high-affinity cMab in micrograms per milliliter v IL6 in picograms per milliliter). These circulating complexes of IL6-cMab are biologically inactive. 2°,% Neutralization of IL6 by the cMab is also indicated by the sharp decrease of CRP levels to below detection limits in 11 patients and an 87% decrease in patient no. 12. Therefore, the absence of any change in thyroid hormone levels is not the result of ineffectiveness of the anti-IL6 cMab to neutralize IL6 activity. Moreover, we also found that endogenous IL6 production in these myeloma patients was nearly completely inhibited during anti-IL6 treatment. 2°
In a previous study, we documented that IL6 administered as a single dose to patients with renal cell carcinoma induced changes in thyroid hormone concentrations within several hours, mimicking the euthyroid sick syndrome. Plasma T3 and TSH concentrations decreased, whereas rT3 levels increased) ° In contrast, prolonged administration of IL6 resulted in normalization of T3 and rT3 concentrations within several weeks. This is in agreement with observations in rodents wherein prolonged administration of cytokines like ILl and TNF resulted in attenuation of the effects of these cytokines on thyroid hormone metabolism. 28 Thus, the effects of cytokines on thyroid hormone metabolism appear to be dependent on the duration of exposure. Boelen et al7 observed a correlation between IL6 concentrations and plasma T3 concentrations in blood samples from patients admitted to a medical ward because of acute illness. In our patients with chronic illness, we did not find this correlation. Although this could be due to the small number of subjects involved, we think that the exposure to chronic rather than to acute elevation of endogenous IL6 production in our patients with multiple myeloma is a more likely explanation. Moreover, Davies et al 9 also postulated that IL6 does not play a role in the pathogenesis of the euthyroid sick syndrome in all types of nonthyroidal illness. In patients with chronic renal disease, they found a high proportion of individuals with low T3 and T4 serum levels, whereas 1L6 levels were relatively low.
Two patients developed infectious complications during or after treatment with anti-IL6 cMabs. In these two patients, a similar pattern of changes in thyroid hormone concentrations occurred: plasma T3 decreased and rT3 increased, reflecting the worsening of a euthyroid sick syndrome. Apparently, high levels of IL6-neutralizing antibodies did not prevent this euthyroid sick syndrome induced by acute infection. In accordance, we have found that infection-induced IL6 production could not be blocked by the anti-IL6 cMab, probably because this endotoxin/TNF-mediated IL6 production by monocytes/ macrophages and/or endothelial cells lacks the positive feedback loop, as we have recently described for myeloma cellinduced IL6 production by bone marrow stroma cells. 2° Moreover, in vitro experiments gave support to this assumption, because IL6 production by monocytes could not be blocked by anti-IL6 Mabs (Aarden LA, Rensink H JAM, van Oers MH, unpublished observations, February 1994). Although our Mab was able to bind infection-induced IL6 (reflected in very high total IL6 levels), the amount of IL6 was too high for it to be complexed totally, resulting in a sharp increase of free IL6, associated with the induction of a euthyroid sick syndrome. Nonetheless, the absolute free IL6 levels were relatively low and even within the range of the (chronically elevated) pretreatmerit IL6 levels. Because rT3 concentrations increased consider-
